OncoQuest, in partnership with a China-based global
pharmaceutical company, has launched a new venture in the

Onco-Immunology space

The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.


OncoQuest is currently conducting a series of phase I/II combinatorial clinical studies in several cancer indications, notably pancreatic and ovarian cancer, to identify an optimal design for a product registration trial. The company firmly believes that based on preclinical data that the coordinated addition of an immune adjuvant and a checkpoint inhibitor may well raise the induced immunity to a new level of clinical significance; expediting clinical development strategies, permitting study in more advanced disease, and in fact raising the bar of performance that would otherwise not be achieved with the use of a checkpoint inhibition alone.  



Oncoquest Treatments

Recent News:


Edmonton Journal Article, December 8, 2016

December 7, 2016

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

November 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study